Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis

被引：2

作者：

Chen, Xuetao ^{[1
,2
,3
]}

Wu, Tingting ^{[1
,2
,3
]}

Du, Zhiyan ^{[4
]}

Kang, Wenjing ^{[1
,2
,3
]}

Xu, Rujun ^{[1
,2
,3
]}

Meng, Fanying ^{[1
,2
,3
]}

Liu, Chihong ^{[1
,2
,3
]}

Chen, Yali ^{[1
,2
,3
]}

Bao, Qichao ^{[1
,2
]}

Shen, Jingkang ^{[4
]}

You, Qidong ^{[1
,2
,3
]}

Cao, Danyan ^{[4
]}

Jiang, Zhengyu ^{[1
,2
,3
]}

Guo, Xiaoke ^{[1
,2
,3
]}

机构：

[1] China Pharmaceut Univ, Jiang Su Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China

[2] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China

[3] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing 210009, Peoples R China

[4] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 265卷

基金：

中国国家自然科学基金; 中国博士后科学基金;

关键词：

BET; BD1; Bromodomain; Brain-permeable; Multiple sclerosis; DRUG DISCOVERY; TARGETING BROMODOMAIN; POTENT; DERIVATIVES; MODELS; FAMILY; SERIES; BROMO; IDENTIFICATION; OPTIMIZATION;

D O I：

10.1016/j.ejmech.2023.116080

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease and lacks effective therapeutic agents. Dysregulation of transcription mediated by bromodomain and extra-terminal domain (BET) proteins containing two different bromodomains (BD1 and BD2) is an important factor in multiple diseases, including MS. Herein, we identified a series of BD1-biased inhibitors, in which compound 16 showed nanomolar potency for BD1 (Kd = 230 nM) and a 60-fold selectivity for BRD4 BD1 over BD2. The co-crystal structure of BRD4 BD1 with 16 indicated that the hydrogen bond interaction of 16 with BD1-specific Asp145 is important for BD1 selectivity. 16 showed favorable brain distribution in mice and PK properties in rats. 16 was able to inhibit microglia activation and had significant therapeutic effects on EAE mice including improvement of spinal cord inflammatory conditions and demyelination protection. Overall, these results suggest that brain-permeable BD1 inhibitors have the potential to be further investigated as therapeutic agents for MS.

引用

页数：14

共 50 条

[21] Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design
Gavai, Ashvinikumar, V
Norris, Derek
Delucca, George
Tortolani, David
Tokarski, John S.
Dodd, Dharmpal
O'Malley, Daniel
Zhao, Yufen
Quesnelle, Claude
Gill, Patrice
Vaccaro, Wayne
Tram Huynh
Ahuja, Vijay
Han, Wen-Ching
Mussari, Christopher
Harikrishnan, Lalgudi
Kamau, Muthoni
Poss, Michael
Sheriff, Steven
Yan, Chunhong
Marsilio, Frank
Menard, Krista
Wen, Mei-Li
Rampulla, Richard
Wu, Dauh-Rurng
Li, Jianqing
Zhang, Huiping
Li, Peng
Sun, Dawn
Yip, Henry
Traeger, Sarah C.
Zhang, Yingru
Mathur, Arvind
Zhang, Haiying
Huang, Christine
Yang, Zheng
Ranasinghe, Asoka
Everlof, Gerry
Raghavan, Nirmala
Tye, Ching Kim
Wee, Susan
Hunt, John T.
Vite, Gregory
Westhouse, Richard
Lee, Francis Y.
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) : 14247 - 14265
[22] Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins
Harrison, Lee A.
Atkinson, Stephen J.
Bassil, Anna
Chung, Chun-wa
Grandi, Paola
Gray, James R. J.
Levernier, Etienne
Lewis, Antonia
Lugo, David
Messenger, Cassie
Michon, Anne-Marie
Mitchell, Darren J.
Preston, Alex
Prinjha, Rab K.
Rioja, Inmaculada
Seal, Jonathan T.
Taylor, Simon
Wall, Ian D.
Watson, Robert J.
Woolven, James M.
Demont, Emmanuel H.
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 10742 - 10771
[23] Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors
Lucas, Simon C. C.
Atkinson, Stephen J.
Chung, Chun-Wa
Davis, Rob
Gordon, Laurie
Grandi, Paola
Gray, James J. R.
Grimes, Thomas
Phillipou, Alexander
Preston, Alex G.
Prinjha, Rab K.
Rioja, Inmaculada
Taylor, Simon
Tomkinson, Nicholas C. O.
Wall, Ian
Watson, Robert J.
Woolven, James
Demont, Emmanuel H.
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 10711 - 10741
[24] Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Seal, Jonathan T.
Atkinson, Stephen J.
Bamborough, Paul
Bassil, Anna
Chung, Chun-Wa
Foley, James
Gordon, Laurie
Grandi, Paola
Gray, James R. J.
Harrison, Lee A.
Kruger, Ryan G.
Matteo, Jeanne J.
McCabe, Michael T.
Messenger, Cassie
Mitchell, Darren
Phillipou, Alex
Preston, Alex
Prinjha, Rab K.
Rianjongdee, Francesco
Rioja, Inmaculada
Taylor, Simon
Wall, Ian D.
Watson, Robert J.
Woolven, James M.
Wyce, Anastasia
Zhang, Xi-Ping
Demont, Emmanuel H.
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 10772 - 10805
[25] TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma
Wang, Zezhou
Choi, Jaehyun
Dove, Peter
Wang, Chunlei
Schimmer, Aaron D.
Petrova, Penka S.
Uger, Robert A.
Slassi, Malik
BLOOD, 2016, 128 (22)
[26] Phase I dose-finding study of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (pts) with advanced malignancies
Bechter, O.
Aftimos, P.
Awada, A.
Rottey, S.
Machiels, J. P.
Dumez, H.
Jungels, C.
Costermans, J.
Huyvaert, N.
Zografos, E.
Meeus, M. A.
Musa, H.
Burkard, U.
Zhao, Y.
Schoffski, P.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E16 - E16
[27] Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors
Li, Zizhou
Xiao, Senhao
Yang, Yaxi
Chen, Chao
Lu, Tian
Chen, Zhifeng
Jiang, Hualiang
Chen, Shijie
Luo, Cheng
Zhou, Bing
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (08) : 3956 - 3975
[28] CC-95775, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients with advanced solid tumors (STs): Results of a phase 1 study
Lesimple, Thierry
de Miguel, Maria Jose
Le Tourneau, Cristophe
Ponz-Sarvise, Mariano
Sablin, Marie Paule
Benito, Diego Salas
Hanna, Bishoy
Chang, Henry
Wei, Xin
Garcia, Marta Ocejo
Lardelli, Pilar
Sanchez, Tania
Palau, Josep Lluis Parra
Nikolova, Zariana
Calvo, Emiliano
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[29] Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors.
Aftimos, Philippe Georges
Bechter, Oliver
Awada, Ahmad
Jungels, Christiane
Dumez, Herlinde
Huyvaert, Nathalie
Costermans, Jo
Lee, Chooi
Meeus, Marie-Anne
Burkard, Ute
Musa, Hanny
Zhao, Yihua
Schoffski, Patrick
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[30] Development and validation of an LC-MS/MS method to quantify the bromodomain and extra-terminal (BET) inhibitor JQ1 in mouse plasma and brain microdialysate: Application to cerebral microdialysis study
Nair, Sreenath
Davis, Abigail
Campagne, Olivia
Schuetz, John D.
Stewart, Clinton F.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 204

← 1 2 3 4 5 →